Related Experiment Video
Updated: Nov 10, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Surface modified multifaceted nanocarriers for oral non-conventional cancer therapy; synthesis and evaluation
Fiza Ur Rehman1, Kehkashan Mazhar2, Annum Malik1
1Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan; Nanosciences and Technology Department, National Centre for Physics, Islamabad, Pakistan.
Abstract:
Inflammatory cells orchestrate tumor niche for the proliferating neoplastic cells, leading to neoangiogenesis, lymphangiogenesis, tumor growth and metastasis. Emergence of severe side effects, multiple drug resistance and associated high cost has rendered conventional chemotherapy less effectual. The aim was to develop a multipurpose, less toxic, more potent and cheaper, oral non-conventional anticancer therapeutic. Cyclooxygenase associated with tumor niche inflammation and proliferative neoplastic cells were targeted synergistically, through anti-inflammatory and anti-proliferative effects of model drug, diclofenac sodium and fluorescent silver nanoparticles (AgNPs), respectively. Drug entrapped AgNPs were surface modified with PVA (for controlling particle size, preferred cellular uptake, evading opsonization and improved dispersion). XRD, FTIR, DSC, TGA, LIBS, particle size and surface plasmon resonance analysis confirmed the efficient drug encapsulation and PVA coating with 62% loading efficiency. In-vitro, the formulation exhibited 1st order release kinetics with sustained and maximal release at slightly acidic conditions (pH 4.5) enabling the potential for passive tumor targeting. Also, nanoparticles showed efficient protein denaturation inhibition potential, hemo-compatibility (<0.8%) and potent anti-cancer activity (P < 0.05) against breast cancer cell line (MCF-7). In-vivo, developed nanoparticles improved pharmacokinetics (2.8 fold increased AUC, 6.9 h t1/2, Cmax = 1.6 ± 0.03 μg/ml, Kel = 0.1) and pharmacodynamics manifested by potent anti-inflammatory, analgesic and anti-pyretic effects (P < 0.05) at 20 fold lower doses. LD50 determination revealed a wide therapeutic window. The study showed promise of synthesized nanomaterials as cheaper, less toxic, hemo-compatible, oral and more potent anti-inflammatory and non-conventional fluorescent anti-cancer agents, vanquishing tumor niche inflammation and repressing proliferation of malignant cells.
Insights
This study developed novel fluorescent silver nanoparticles (AgNPs) loaded with diclofenac sodium for oral cancer therapy. These AgNPs offer a less toxic, more potent, and cheaper alternative to conventional chemotherapy by targeting tumor inflammation and proliferation.
Area of Science:
- Nanomedicine
- Materials Science
- Pharmacology
Background:
- Conventional chemotherapy faces limitations due to severe side effects, drug resistance, and high costs.
- Tumor microenvironments are characterized by inflammation, promoting cancer growth and metastasis.
- There is a need for novel, cost-effective, and less toxic oral anticancer therapeutics.
Purpose of the Study:
- To develop a multipurpose, oral, non-conventional anticancer therapeutic agent.
- To synergistically target tumor inflammation and neoplastic cell proliferation.
- To create a cheaper, less toxic, and more potent alternative to existing cancer treatments.
Main Methods:
- Synthesized diclofenac sodium-entrapped silver nanoparticles (AgNPs) surface-modified with polyvinyl alcohol (PVA).
- Characterized the formulation using XRD, FTIR, DSC, TGA, LIBS, particle size, and SPR analysis.
- Evaluated in-vitro drug release kinetics, protein denaturation inhibition, hemocompatibility, and anticancer activity against MCF-7 cells.
- Assessed in-vivo pharmacokinetics, pharmacodynamics (anti-inflammatory, analgesic, antipyretic effects), and LD50.
Main Results:
- Efficient drug encapsulation (62% loading) and PVA coating confirmed.
- Sustained drug release at pH 4.5, indicating potential for passive tumor targeting.
- Demonstrated hemocompatibility (<0.8%) and potent in-vitro anticancer activity (P < 0.05).
- Improved in-vivo pharmacokinetics and significant anti-inflammatory, analgesic, and antipyretic effects at 20-fold lower doses.
- LD50 determination revealed a wide therapeutic window.
Conclusions:
- Synthesized nanomaterials show promise as oral, fluorescent anticancer agents.
- The formulation effectively targets tumor inflammation and inhibits cancer cell proliferation.
- Offers a cheaper, less toxic, and more potent therapeutic option compared to conventional chemotherapy.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

